Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:ACHN
CUSIP: 00448Q20
Web: www.achillion.com

Capitalization:

Market Cap: $527.9 million
Outstanding Shares: 136,761,000

Average Prices:

50 Day Moving Avg: $4.48
200 Day Moving Avg: $4.20
52 Week Range: $3.15 - $9.19

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -5.45
P/E Growth: -0.31

Sales & Book Value:

Annual Revenue: $15 million
Price / Sales: 37.29
Book Value: $2.65 per share
Price / Book: 1.54

Profitability:

EBIDTA: ($70,510,000.00)
Return on Equity: -17.56%
Return on Assets: -16.97%

Debt:

Current Ratio: 25.33%
Quick Ratio: 25.33%

Misc:

Average Volume: 1.98 million shs.
Beta: 1.9
Short Ratio: 9.2

Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). During the same quarter last year, the business posted ($0.14) EPS. View Achillion Pharmaceuticals' Earnings History.

When will Achillion Pharmaceuticals make its next earnings announcement?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Achillion Pharmaceuticals.

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 1-year target prices for Achillion Pharmaceuticals' stock. Their forecasts range from $4.00 to $13.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $6.75 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Some companies that are related to Achillion Pharmaceuticals include Xencor (XNCR), NeuroDerm (NDRM), Five Prime Therapeutics (FPRX), Athenex (ATNX), Omeros Corporation (OMER), Ascendis Pharma A/S (ASND), REGENXBIO (RGNX), ZIOPHARM Oncology (ZIOP), Intra-Cellular Therapies (ITCI), Amarin Corporation PLC (AMRN), Retrophin (RTRX), PTC Therapeutics (PTCT), Keryx Biopharmaceuticals (KERX), Flexion Therapeutics (FLXN), Akebia Therapeutics (AKBA), Vanda Pharmaceuticals (VNDA), Aduro Biotech (ADRO) and Reata Pharmaceuticals (RETA).

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:

David I. Scheer, Chairman of the Board
Milind S. Deshpande Ph.D., President, Chief Executive Officer, Director
Mary Kay Fenton CPA, Chief Financial Officer, Executive Vice President
Martha E. Manning Esq., Executive Vice President, General Counsel, Corporate Secretary
David Apelian M.D. Ph.D., Executive Vice President, Chief Medical Officer
Joseph Truitt, Executive Vice President, Chief Commercial Officer
Amy Jennings, Senior Vice President - Regulatory Affairs
Michael D. Kishbauch, Director
Frank Verwiel M.D., Director
Jason S. Fisherman M.D., Independent Director

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include RA Capital Management LLC (9.97%), Vanguard Group Inc. (7.00%), Janus Henderson Group PLC (3.31%), State Street Corp (2.91%), Numeric Investors LLC (2.15%) and Dimensional Fund Advisors LP (1.37%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, State Street Corp, Emory University, Numeric Investors LLC, PDT Partners LLC, Northern Trust Corp, Pacad Investment Ltd. and AXA. View Insider Buying and Selling for Achillion Pharmaceuticals.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dimensional Fund Advisors LP, Senzar Asset Management LLC, EcoR1 Capital LLC, JPMorgan Chase & Co., FMR LLC, Los Angeles Capital Management & Equity Research Inc. and GSA Capital Partners LLP. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.09.

MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		301 (Vote Outperform)
Underperform Votes:		225 (Vote Underperform)
Total Votes:		526

MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	3 Hold Ratings, 4 Buy Ratings
Consensus Rating:	Buy (Score: 2.57)
Consensus Price Target:	$6.75 (65.04% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/17/2017	Chardan Capital	Reiterated Rating	Neutral		High
9/12/2017	Ladenburg Thalmann Financial Services	Lower Price Target	Buy -> Buy	$9.00 -> $6.50	High
9/12/2017	Robert W. Baird	Reiterated Rating	Neutral	$5.00 -> $4.00	High
8/9/2017	Maxim Group	Set Price Target	Buy	$5.00 -> $7.00	High
5/18/2017	Leerink Swann	Upgrade	Market Perform -> Outperform	$4.00 -> $6.00	High
4/26/2017	Jefferies Group LLC	Reiterated Rating	Hold		Low
11/3/2016	Wedbush	Reiterated Rating	Outperform	$13.00	N/A
9/15/2016	FBR & Co	Initiated Coverage	Outperform	$16.00	N/A
7/7/2016	JMP Securities	Upgrade	Market Perform -> Outperform	$13.00	N/A
12/8/2015	William Blair	Reiterated Rating	Outperform	$16.00	N/A

(Data available from 9/21/2015 forward)

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ ACHN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/1/2017		($0.17)					N/A
8/8/2017	Q2 2017	($0.16)	($0.16)			View	Listen
5/4/2017	Q1 2017	($0.16)	($0.15)			View	N/A
2/23/2017	Q4 2016	($0.18)	($0.03)		$15.00 million	View	N/A
11/3/2016	Q3	($0.16)	($0.15)			View	N/A
8/4/2016	Q2	($0.15)	($0.14)			View	N/A
5/3/2016	Q116	($0.14)	($0.13)			View	N/A
2/25/2016	Q4	$0.09	$0.12	$31.40 million	$31.60 million	View	N/A
11/5/2015	Q3	$0.09	$0.19	$32.62 million	$33.82 million	View	N/A
8/10/2015	Q2	($0.18)	($0.25)		$0.71 million	View	N/A
5/7/2015	Q115	($0.22)	($0.17)			View	N/A
3/5/2015	Q414	($0.19)	($0.21)			View	N/A
11/4/2014	Q314	($0.18)	($0.16)			View	N/A
8/7/2014	Q214	($0.18)	($0.16)			View	N/A
5/7/2014	Q114	($0.17)	($0.17)			View	N/A
3/7/2014	Q413	($0.16)	($0.14)	$0.01 million		View	N/A
11/12/2013	Q3	($0.20)	($0.14)			View	N/A
5/7/2013	Q113	($0.15)	($0.14)			View	N/A
11/8/2012	Q312	($0.17)	($0.20)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

2017 EPS Consensus Estimate: ($0.71)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	($0.17)	($0.16)	($0.17)
Q2 2017	3	($0.17)	($0.17)	($0.17)
Q3 2017	3	($0.18)	($0.18)	($0.18)
Q4 2017	1	($0.19)	($0.19)	($0.19)

(Data provided by Zacks Investment Research)

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 74.11%

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/22/2016	Jason S Fisherman	Director	Buy	10,000	$3.96	$39,600.00
12/5/2016	Mary Kay Fenton	CFO	Buy	2,500	$4.11	$10,275.00
12/2/2016	Joel C Barrish	Insider	Buy	2,500	$4.06	$10,150.00
12/30/2015	David Apelian	insider	Sell	10,000	$10.50	$105,000.00
12/28/2015	Mary Kay Fenton	CFO	Sell	43,500	$10.08	$438,480.00
11/11/2015	Nicole Vitullo	Director	Sell	550,000	$10.17	$5,593,500.00
9/25/2015	Nicole Vitullo	Director	Sell	9,310	$8.22	$76,528.20
1/23/2015	Mary Kay Fenton	CFO	Sell	13,125	$16.00	$210,000.00
1/21/2015	Milind Deshpande	CEO	Sell	100,000	$15.00	$1,500,000.00
9/30/2014	Ra Capital Management, Llc	Insider	Sell	1,332,014	$10.20	$13,586,542.80
9/29/2014	Ra Capital Management, Llc	Insider	Sell	221,014	$10.96	$2,422,313.44
9/26/2014	Ra Capital Management, Llc	Major Shareholder	Sell	2,372,915	$11.17	$26,505,460.55
9/25/2014	Ra Capital Management, Llc	Major Shareholder	Sell	497,986	$11.05	$5,502,745.30
9/24/2014	Ra Capital Management, Llc	Major Shareholder	Sell	1,204,929	$11.27	$13,579,549.83
9/23/2014	Ra Capital Management, Llc	Major Shareholder	Sell	2,595,071	$11.29	$29,298,351.59
9/2/2014	Ra Capital Management, Llc	Major Shareholder	Sell	835,293	$11.63	$9,714,457.59
8/27/2014	Ra Capital Management, Llc	Major Shareholder	Sell	2,711,352	$11.33	$30,719,618.16
8/26/2014	Ra Capital Management, Llc	Major Shareholder	Sell	2,112,867	$11.35	$23,981,040.45
8/25/2014	Joseph Truitt	EVP	Sell	25,000	$10.82	$270,500.00
8/25/2014	Ra Capital Management, Llc	Major Shareholder	Sell	331,396	$10.96	$3,632,100.16
8/18/2014	Milind Deshpande	CEO	Sell	216,624	$10.00	$2,166,240.00
8/18/2014	Ra Capital Management, Llc	Major Shareholder	Sell	4,235,000	$9.53	$40,359,550.00
8/15/2014	Michael D Kishbauch	Director	Sell	495,812	$9.40	$4,660,632.80
8/13/2014	Gary E Frashier	Director	Sell	5,000	$8.00	$40,000.00
6/20/2014	Ra Capital Management, Llc	Insider	Sell	880,000	$8.40	$7,392,000.00
6/16/2014	Gary E Frashier	Director	Sell	55,000	$8.00	$440,000.00
6/16/2014	Joseph Truitt	EVP	Sell	25,000	$7.82	$195,500.00
6/16/2014	Qvt Associates Gp Llc	Major Shareholder	Sell	1,819,551	$7.70	$14,010,542.70
6/11/2014	Qvt Associates Gp Llc	Major Shareholder	Sell	128,649	$7.66	$985,451.34
6/10/2014	Joseph Truitt	EVP	Sell	50,000	$6.02	$301,000.00
6/10/2014	Michael D Kishbauch	Director	Sell	371,937	$7.75	$2,882,511.75
12/30/2013	Qvt Associates Gp Llc	major shareholder	Sell	170,239	$3.34	$568,598.26
12/26/2013	Qvt Associates Gp Llc	major shareholder	Sell	121,205	$3.44	$416,945.20
12/23/2013	Qvt Associates Gp Llc	major shareholder	Sell	289,141	$3.24	$936,816.84
12/19/2013	Qvt Associates Gp Llc	major shareholder	Sell	222,612	$3.09	$687,871.08
12/17/2013	Qvt Associates Gp Llc	major shareholder	Sell	92,803	$3.11	$288,617.33
11/22/2013	Dennis Liotta	Director	Buy	10,000	$2.98	$29,800.00
11/20/2013	Ra Capital Management, Llc	Insider	Buy	1,110,000	$2.55	$2,830,500.00
11/19/2013	Jason Fisherman	Director	Buy	15,000	$2.63	$39,450.00
11/12/2013	Ra Capital Management, Llc	Insider	Buy	1,795,000	$2.48	$4,451,600.00
10/31/2013	Ra Capital Management, Llc	Insider	Buy	1,186,007	$2.45	$2,905,717.15
10/14/2013	Ra Capital Management, Llc	Insider	Buy	2,369,229	$2.79	$6,610,148.91
10/11/2013	Ra Capital Management, Llc	Insider	Buy	2,448,710	$2.56	$6,268,697.60
9/30/2013	Ra Capital Management, Llc	Insider	Buy	2,800,000	$2.98	$8,344,000.00
8/14/2013	Jason Fisherman	Director	Buy	5,000	$6.83	$34,150.00
8/12/2013	Dennis Liotta	Director	Buy	5,000	$6.47	$32,350.00
8/9/2013	Qvt Associates Gp Llc	major shareholder	Buy	102,282	$6.41	$655,627.62
7/11/2013	Qvt Associates Gp Llc	Major Shareholder	Buy	401,017	$6.46	$2,590,569.82
7/10/2013	Qvt Associates Gp Llc	Major Shareholder	Buy	390,944	$6.33	$2,474,675.52
7/8/2013	Qvt Associates Gp Llc	Major Shareholder	Buy	642,509	$6.28	$4,034,956.52
7/3/2013	Qvt Associates Gp Llc	Major Shareholder	Buy	1,963,248	$6.43	$12,623,684.64
7/1/2013	Gary E Frashier	Director	Sell	5,000	$8.17	$40,850.00
6/21/2013	Jason S Fisherman	Director	Buy	10,000	$7.63	$76,300.00
6/7/2013	Gary E Frashier	Director	Sell	5,000	$8.37	$41,850.00
6/3/2013	Jason S Fisherman	Director	Buy	10,000	$7.87	$78,700.00

(Data available from 1/1/2013 forward)

Headline Trends for Achillion Pharmaceuticals (NASDAQ:ACHN) Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)

Source:

Date	Headline
	Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series feeds.benzinga.com - September 20 at 6:55 AM
	Achillion Pharmaceuticals, Inc. (ACHN) Given Neutral Rating at Chardan Capital www.americanbankingnews.com - September 20 at 6:26 AM
	-$0.18 Earnings Per Share Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter www.americanbankingnews.com - September 18 at 12:28 AM
	Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - September 15 at 12:26 AM
	Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post FY2018 Earnings of ($0.79) Per Share www.americanbankingnews.com - September 13 at 1:22 PM
	Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends - CNBC www.cnbc.com - September 12 at 3:32 PM
	Achillion's HCV Partnership with J&J Terminated, Stock Falls - Nasdaq www.nasdaq.com - September 12 at 3:31 PM
	Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Idera Pharmaceuticals finance.yahoo.com - September 12 at 3:31 PM
	Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : September 12, 2017 finance.yahoo.com - September 12 at 3:31 PM
	Achillion's HCV Partnership with J&J Terminated, Stock Falls finance.yahoo.com - September 12 at 3:31 PM
	Ladenburg Thalmann Financial Services Lowers Achillion Pharmaceuticals, Inc. (ACHN) Price Target to $6.50 www.americanbankingnews.com - September 12 at 10:48 AM
	Achillion Pharmaceuticals, Inc. (ACHN) Downgraded by ValuEngine www.americanbankingnews.com - September 11 at 11:32 PM
	18 Stocks Moving In Monday's Pre-Market Session - Benzinga www.benzinga.com - September 11 at 4:00 PM
	18 Stocks Moving In Monday's Pre-Market Session - Benzinga www.benzinga.com - September 11 at 4:00 PM
	Pre-Market Most Active for Sep 11, 2017 : TEVA, AZN, MRNS, BAC, TVIX, QQQ, AAPL, SNAP, USLV, ACHN, UN, MFGP - Nasdaq www.nasdaq.com - September 11 at 4:00 PM
	Pre-Market Most Active for Sep 11, 2017 : TEVA, AZN, MRNS, BAC, TVIX, QQQ, AAPL, SNAP, USLV, ACHN, UN, MFGP - Nasdaq www.nasdaq.com - September 11 at 4:00 PM
	Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge - Nasdaq www.nasdaq.com - September 11 at 4:00 PM
	Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge - Nasdaq www.nasdaq.com - September 11 at 4:00 PM
	Achillion Pharma (ACHN) Reports Termination of Collaboration for Hepatitis C With Janssen (JNJ) - StreetInsider.com www.streetinsider.com - September 11 at 4:00 PM
	Achillion Pharma (ACHN) Reports Termination of Collaboration for Hepatitis C With Janssen (JNJ) - StreetInsider.com www.streetinsider.com - September 11 at 4:00 PM
	Achillion Pharma (ACHN) Promotes Joseph Truitt to COO - StreetInsider.com www.streetinsider.com - September 11 at 4:00 PM
	Achillion Pharma (ACHN) Promotes Joseph Truitt to COO - StreetInsider.com www.streetinsider.com - September 11 at 4:00 PM
	Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen finance.yahoo.com - September 11 at 4:00 PM
	Achillion Announces Strengthening of Management Team finance.yahoo.com - September 11 at 4:00 PM
	Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends finance.yahoo.com - September 11 at 4:00 PM
	Achillion Pharma Slides After Hep C Deal Is Terminated finance.yahoo.com - September 11 at 4:00 PM
	Achillion Shares Are Plunging on Termination of Hepatitis C Pact finance.yahoo.com - September 11 at 3:59 PM
	Achillion Pharmaceuticals, Inc. (ACHN) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - September 5 at 8:54 AM
	Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - August 20 at 9:28 PM
	Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - August 11 at 5:06 PM
	Corporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D Inhibitor finance.yahoo.com - August 11 at 3:49 PM
	Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - August 11 at 2:14 PM
	Leerink Swann Comments on Achillion Pharmaceuticals, Inc.'s FY2017 Earnings (ACHN) www.americanbankingnews.com - August 11 at 12:04 PM
	William Blair Research Analysts Cut Earnings Estimates for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) www.americanbankingnews.com - August 11 at 12:04 PM
	Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals finance.yahoo.com - August 10 at 4:51 PM
	Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 10, 2017 finance.yahoo.com - August 10 at 4:51 PM
	Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence finance.yahoo.com - August 10 at 4:51 PM
	Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Lowered by Robert W. Baird www.americanbankingnews.com - August 10 at 2:16 PM
	Health Care Sector Update for 08/09/2017: ACHN,NTRA,SGRY - Nasdaq www.nasdaq.com - August 10 at 1:48 AM
	Edited Transcript of ACHN earnings conference call or presentation 8-Aug-17 8:05pm GMT finance.yahoo.com - August 9 at 8:46 PM
	Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update finance.yahoo.com - August 9 at 8:46 PM
	3 Biotech Stocks Under the Microscope on Wednesday 8/9/17 finance.yahoo.com - August 9 at 8:46 PM
	Maxim Group Analysts Give Achillion Pharmaceuticals, Inc. (ACHN) a $7.00 Price Target www.americanbankingnews.com - August 9 at 6:46 PM
	Achillion Pharmaceuticals, Inc. (ACHN) Releases Earnings Results, Meets Expectations www.americanbankingnews.com - August 9 at 4:08 PM
	BUZZ-US STOCKS ON THE MOVE-Priceline, Hertz, Natera, Surgical Partners - Nasdaq www.nasdaq.com - August 9 at 3:44 PM
	2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July finance.yahoo.com - August 9 at 3:44 PM
	Why Achillion Pharmaceuticals Is Shooting 25% Higher Today www.fool.com - August 9 at 2:04 PM
	2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July www.fool.com - August 9 at 2:04 PM
	Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Price Target Cut to $4.00 www.americanbankingnews.com - August 9 at 9:00 AM
	Achillion shares rally as blood disorder treatment shows promise - MarketWatch www.marketwatch.com - August 9 at 1:33 AM